Kenvue Inc. (NYSE:KVUE – Get Free Report) shares hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $23.54 and last traded at $23.45, with a volume of 572035 shares trading hands. The stock had previously closed at $23.39.
Wall Street Analysts Forecast Growth
KVUE has been the topic of a number of recent research reports. Citigroup dropped their target price on Kenvue from $21.00 to $20.00 and set a “neutral” rating on the stock in a research report on Wednesday, July 10th. Royal Bank of Canada reissued an “outperform” rating and set a $24.00 price target on shares of Kenvue in a research report on Wednesday, August 7th. JPMorgan Chase & Co. raised their price objective on Kenvue from $22.00 to $24.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. Deutsche Bank Aktiengesellschaft boosted their target price on Kenvue from $23.00 to $24.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Finally, UBS Group raised their price target on Kenvue from $20.00 to $22.00 and gave the company a “neutral” rating in a report on Wednesday, August 7th. One analyst has rated the stock with a sell rating, six have issued a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, Kenvue has an average rating of “Hold” and a consensus price target of $21.44.
View Our Latest Stock Analysis on KVUE
Kenvue Stock Performance
Kenvue (NYSE:KVUE – Get Free Report) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.28 by $0.04. Kenvue had a return on equity of 21.80% and a net margin of 7.23%. The firm had revenue of $4 billion during the quarter, compared to the consensus estimate of $3.93 billion. During the same period last year, the business posted $0.32 EPS. The business’s revenue was down .3% compared to the same quarter last year. Equities research analysts anticipate that Kenvue Inc. will post 1.08 EPS for the current year.
Kenvue Increases Dividend
The company also recently disclosed a quarterly dividend, which was paid on Wednesday, August 28th. Shareholders of record on Wednesday, August 14th were paid a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a yield of 3.53%. The ex-dividend date was Wednesday, August 14th. This is a boost from Kenvue’s previous quarterly dividend of $0.20. Kenvue’s dividend payout ratio (DPR) is 105.13%.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Marathon Capital Management boosted its holdings in shares of Kenvue by 0.3% in the 2nd quarter. Marathon Capital Management now owns 149,699 shares of the company’s stock worth $2,722,000 after buying an additional 514 shares during the last quarter. Manchester Capital Management LLC lifted its stake in Kenvue by 80.8% in the first quarter. Manchester Capital Management LLC now owns 1,186 shares of the company’s stock valued at $25,000 after purchasing an additional 530 shares during the last quarter. Poehling Capital Management INC. raised its stake in shares of Kenvue by 0.5% in the second quarter. Poehling Capital Management INC. now owns 104,934 shares of the company’s stock valued at $1,908,000 after buying an additional 547 shares during the period. Pathway Financial Advisers LLC lifted its position in shares of Kenvue by 12.0% during the 2nd quarter. Pathway Financial Advisers LLC now owns 5,131 shares of the company’s stock valued at $93,000 after buying an additional 549 shares during the last quarter. Finally, Tradition Wealth Management LLC raised its stake in Kenvue by 2.8% in the 4th quarter. Tradition Wealth Management LLC now owns 21,278 shares of the company’s stock valued at $458,000 after acquiring an additional 575 shares during the period. 97.64% of the stock is currently owned by hedge funds and other institutional investors.
Kenvue Company Profile
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Recommended Stories
- Five stocks we like better than Kenvue
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- 5 Oversold Stocks to Buy Right Now
- Investing In Automotive Stocks
- Congress Members Are Buying These 3 Hot Stocks
- What is the Dow Jones Industrial Average (DJIA)?
- Moderna’s Recent Drop: 4 Reasons Bulls See Opportunity
Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.